Vitamin D actions on CD4+ T cells in autoimmune disease

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Hayes, Colleen Elizabeth ^a   Hubler, Shane L ^a   Moore, Jerott R ^a   Barta, Lauren E ^a   Praska, Corinne E ^a   Nashold, Faye E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Autoimmune diseases; CD4 positive T lymphocytes; Multiple sclerosis; Type 1 diabetes; Vitamin D

Indexed keywords

CALCITRIOL; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ECALECTIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 9; MEMBRANE COFACTOR PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHOLIPASE C GAMMA1; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTING CELL; APOPTOSIS; ASTHMA; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL INTERACTION; CROSS REACTION; DNA POLYMORPHISM; ENZYME ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE REGULATORY NETWORK; GENETIC TRANSCRIPTION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IPEX SYNDROME; LIGHT EXPOSURE; MORTALITY; MULTIPLE SCLEROSIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SUNLIGHT; TH1 CELL; TH17 CELL; THYMOCYTE; ULTRAVIOLET RADIATION; UPREGULATION; VITAMIN D METABOLISM;

EID: 84926643679     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00100     Document Type: Review

References (330)

1. Blumberg RS, Dittel B, Hafler D, von Herrath M, Nestle FO. Unraveling the autoimmune translational research process layer by layer. Nat Med (2012) 18:35-41. doi:10.1038/nm.2632
2. Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol (2013) 13:128. doi:10.1186/1471-2377-13-128
3. Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology (2013) 40:195-210. doi:10.1159/000342779
4. Patterson C, Guariguata L, Dahlquist G, Soltesz G, Ogle G, Silink M. Diabetes in the young-a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract (2014) 103:161-75. doi:10.1016/j.diabres.2013.11.005
5. Singleton AB. Genetics. A unified process for neurological disease. Science (2014) 343:497-8. doi:10.1126/science.1250172
6. Hayes CE, Nelson CD, Spanier JA. Vitamin D and autoimmunity. In: Gombart AF, editor. Vitamin D: Oxidation, Immunity, and Aging. Boca Raton: Taylor & Francis Group, CRC Press (2012). p. 239-306.
7. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev (2012) 12:127-36. doi:10.1016/j.autrev.2012.07.007
8. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol (2014) 10:225-38. doi:10.1038/nrneurol.2014.37
9. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet (2014) 383:69-82. doi:10.1016/S0140-6736(13)60591-7
10. Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 13:243-56. doi:10.1038/nri3422
11. Chao MJ, Ramagopalan SV, Herrera BM, Orton SM, Handunnetthi L, Lincoln MR, et al. MHC transmission: insights into gender bias in MS susceptibility. Neurology (2011) 76:242-6. doi:10.1212/WNL.0b013e318207b060
12. Isobe N, Damotte V, Lo Re V, Ban M, Pappas D, Guillot-Noel L, et al. Genetic burden in multiple sclerosis families. Genes Immun (2013) 14:434-40. doi:10.1038/gene.2013.37
13. Steck AK, Rewers MJ. Genetics of type 1 diabetes. Clin Chem (2011) 57:176-85. doi:10.1373/clinchem.2010.148221
14. Baranzini SE, Mudge J, van Velkinburgh JC, Khankhanian P, Khrebtukova I, Miller NA, et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature (2010) 464:1351-6. doi:10.1038/nature08990
15. Stefan M, Zhang W, Concepcion E, Yi Z, Tomer Y. DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects on etiology. J Autoimmun (2014) 50:33-7. doi:10.1016/j.jaut.2013.10.001
16. Halfvarson J. Genetics in twins with Crohn's disease: less pronounced than previously believed? Inflamm Bowel Dis (2011) 17:6-12. doi:10.1002/ibd.21295
17. Petersen BS, Spehlmann ME, Raedler A, Stade B, Thomsen I, Rabionet R, et al. Whole genome and exome sequencing of monozygotic twins discordant for Crohn's disease. BMC Genomics (2014) 15:564. doi:10.1186/1471-2164-15-564
18. Furukawa H, Oka S, Matsui T, Hashimoto A, Arinuma Y, Komiya A, et al. Genome, epigenome and transcriptome analyses of a pair of monozygotic twins discordant for systemic lupus erythematosus. Hum Immunol (2013) 74:170-5. doi:10.1016/j.humimm.2012.11.007
19. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol (2010) 6:156-66. doi:10.1038/nrneurol.2010.1
20. Ebers G. Interactions of environment and genes in multiple sclerosis. J Neurol Sci (2013) 334:161-3. doi:10.1016/j.jns.2013.08.018
21. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiatr Scand Suppl (1960) 35(Suppl 147):132-47. doi:10.1111/j.1600-0447.1960.tb08674.x
22. Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry (2011) 82:1132-41. doi:10.1136/jnnp.2011.240432
23. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol (2008) 7:268-77. doi:10.1016/S1474-4422(08)70042-5
24. Dyment DA, Yee IM, Ebers GC, Sadovnick AD, G. Canadian Collaborative Study. Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. J Neurol Neurosurg Psychiatry (2006) 77:258-9. doi:10.1136/jnnp.2005.063008
25. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol (2006) 5:932-6. doi:10.1016/S1474-4422(06)70581-6
26. Orton SM, Ramagopalan SV, Brocklebank D, Herrera BM, Dyment DA I, Yee IM, et al. Effect of immigration on multiple sclerosis sex ratio in Canada: the Canadian collaborative study. J Neurol Neurosurg Psychiatry (2010) 81:31-6. doi:10.1136/jnnp.2008.162784
27. Sadovnick AD. European Charcot foundation lecture: the natural history of multiple sclerosis and gender. J Neurol Sci (2009) 286:1-5. doi:10.1016/j.jns.2009.09.005
28. McKenzie RL, Liley JB, Bjorn LO. UV radiation: balancing risks and benefits. Photochem Photobiol (2009) 85:88-98. doi:10.1111/j.1751-1097.2008.00400.x
29. Embry AF, Snowdon LR, Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol (2000) 48:271-2. doi:10.1002/1531-8249(200008)48:2<271::AID-ANA28>3.3.CO;2-F
30. Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry (2008) 79:152-7. doi:10.1136/jnnp.2006.105320
31. Meier DS, Balashov KE, Healy B, Weiner HL, Guttmann CR. Seasonal prevalence of MS disease activity. Neurology (2010) 75:799-806. doi:10.1212/WNL.0b013e3181f0734c
32. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ (2003) 327:316. doi:10.1136/bmj.327.7410.316
33. Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic circle. J Neurol (2007) 254:471-7. doi:10.1007/s00415-006-0395-5
34. Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology (2007) 69:381-8. doi:10.1212/01.wnl.0000268266.50850.48
35. McDowell TY, Amr S, Culpepper WJ, Langenberg P, Royal W, Bever C, et al. Sun exposure, vitamin D and age at disease onset in relapsing multiple sclerosis. Neuroepidemiology (2011) 36:39-45. doi:10.1159/000322512
36. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health (2004) 58:142-4. doi:10.1136/jech.58.2.142
37. Mohr SB, Garland CF, Gorham ED, Garland FC. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia (2008) 51:1391-8. doi:10.1007/s00125-008-1061-5
38. Moltchanova EV, Schreier N, Lammi N, Karvonen M. Seasonal variation of diagnosis of Type 1 diabetes mellitus in children worldwide. Diabet Med (2009) 26:673-8. doi:10.1111/j.1464-5491.2009.02743.x
39. Staples JA, Ponsonby AL, Lim LL, McMichael AJ. Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ Health Perspect (2003) 111:518-23. doi:10.1289/ehp.5941
40. Godar DE. UV doses worldwide. Photochem Photobiol (2005) 81:736-49. doi:10.1111/j.1751-1097.2005.tb01438.x
41. Sloka S, Grant M, Newhook LA. Time series analysis of ultraviolet B radiation and type 1 diabetes in Newfoundland. Pediatr Diabetes (2008) 9:81-6. doi:10.1111/j.1399-5448.2007.00310.x
42. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother (2013) 13:3-9. doi:10.1586/14737175.2013.865866
43. Lossius A, Riise T, Pugliatti M, Bjornevik K, Casetta I, Drulovic J, et al. Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Mult Scler (2014) 20:669-74. doi:10.1177/1352458513505693
44. Ascherio A, Munger KL. Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol (2010) 5:271-7. doi:10.1007/s11481-010-9201-3
45. Disanto G, Meier U, Giovannoni G, Ramagopalan SV. Vitamin D: a link between Epstein-Barr virus and multiple sclerosis development? Expert Rev Neurother (2011) 11:1221-4. doi:10.1586/ern.11.97
46. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med (1997) 216:21-7. doi:10.3181/00379727-216-44153A
47. Smolders J, Damoiseaux J. Vitamin D as a T-cell modulator in multiple sclerosis. Vitam Horm (2011) 86:401-28. doi:10.1016/B978-0-12-386960-9.00018-6
48. D'Aurizio F, Villalta D, Metus P, Doretto P, Tozzoli R. Is vitamin D a player or not in the pathophysiology of autoimmune thyroid diseases? Autoimmun Rev (2014). doi:10.1016/j.autrev.2014.10.008
49. Lopez ER, Regulla K, Pani MA, Krause M, Usadel KH, Badenhoop K. CYP27B1 polymorphisms variants are associated with type 1 diabetes mellitus in Germans. J Steroid Biochem Mol Biol (2004) 89-90:155-7. doi:10.1016/j.jsbmb.2004.03.095
50. Bailey R, Cooper JD, Zeitels L, Smyth DJ, Yang JH, Walker NM, et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes (2007) 56:2616-21. doi:10.2337/db07-0652
51. Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K. CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev (2007) 23:631-6. doi:10.1002/dmrr.719
52. Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, Wallace C, et al. Inherited variation in vitamin d genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes (2011) 60:1624-31. doi:10.2337/db10-1656
53. Hussein AG, Mohamed RH, Alghobashy AA. Synergism of CYP2R1 and CYP27B1 polymorphisms and susceptibility to type 1 diabetes in Egyptian children. Cell Immunol (2012) 279:42-5. doi:10.1016/j.cellimm.2012.08.006
54. Frederiksen BN, Kroehl M, Fingerlin TE, Wong R, Steck AK, Rewers M, et al. Association between vitamin D metabolism gene polymorphisms and risk of islet autoimmunity and progression to type 1 diabetes: the diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab (2013) 98:E1845-51. doi:10.1210/jc.2013-2256
55. Fichna M, Zurawek M, Januszkiewicz-Lewandowska D, Gryczynska M, Fichna P, Sowinski J, et al. Association of the CYP27B1 C(-1260)A polymorphism with autoimmune Addison's disease. Exp Clin Endocrinol Diabetes (2010) 118:544-9. doi:10.1055/s-0029-1241206
56. Lopez ER, Zwermann O, Segni M, Meyer G, Reincke M, Seissler J, et al. A promoter polymorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 diabetes mellitus in Germans. Eur J Endocrinol (2004) 151:193-7. doi:10.1530/eje.0.1510193
57. Torkildsen O, Knappskog PM, Nyland HI, Myhr KM. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch Neurol (2008) 65:809-11. doi:10.1001/archneur.65.6.809
58. Ramagopalan SV, Dyment DA, Cader MZ, Morrison KM, Disanto G, Morahan JM, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol (2011) 70:881-6. doi:10.1002/ana.22678
59. Alcina A, Fedetz M, Fernandez O, Saiz A, Izquierdo G, Lucas M, et al. Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis. J Med Genet (2013) 50:25-33. doi:10.1136/jmedgenet-2012-101085
60. Ross JP, Bernales CQ, Lee JD, Sadovnick AD, Traboulsee AL, Vilarino-Guell C. Analysis of CYP27B1 in multiple sclerosis. J Neuroimmunol (2014) 266:64-6. doi:10.1016/j.jneuroim.2013.11.006
61. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 476:214-9. doi:10.1038/nature10251
62. Pociot F, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G, et al. Genetics of type 1 diabetes: what's next? Diabetes (2010) 59:1561-71. doi:10.2337/db10-0076
63. Barizzone N, Pauwels I, Luciano B, Franckaert D, Guerini FR, Cosemans L, et al. No evidence for a role of rare CYP27B1 functional variations in multiple sclerosis. Ann Neurol (2013) 73:433-7. doi:10.1002/ana.23834
64. Ban M, Caillier S I, Mero L, Myhr KM, Celius EG, Aarseth J, et al. No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Ann Neurol (2013) 73:430-2. doi:10.1002/ana.23833
65. Reinthaler E, Machetanz G, Hotzy C, Reindl M, Fazekas F, Kristoferitsch W, et al. No evidence for a role of rare CYP27B1 variants in Austrian multiple sclerosis patients. Mult Scler (2014) 20:391-2. doi:10.1177/1352458513498130
66. Smolders J, Peelen E, Thewissen M, Menheere P, Cohen Tervaert JW, Hupperts R, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev (2009) 8:621-6. doi:10.1016/j.autrev.2009.02.009
67. Berlanga-Taylor AJ, Disanto G, Ebers GC, Ramagopalan SV. Vitamin D-gene interactions in multiple sclerosis. J Neurol Sci (2011) 311:32-6. doi:10.1016/j.jns.2011.08.041
68. Huang J, Xie ZF. Polymorphisms in the vitamin D receptor gene and multiple sclerosis risk: a meta-analysis of case-control studies. J Neurol Sci (2012) 313:79-85. doi:10.1016/j.jns.2011.09.024
69. Niino M, Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Tashiro K. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci (2000) 177:65-71. doi:10.1016/S0022-510X(00)00336-1
70. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet (2009) 5:e1000369. doi:10.1371/journal.pgen.1000369
71. Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res (1998) 13:1691-9. doi:10.1359/jbmr.1998.13.11.1691
72. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol (2000) 14:401-20. doi:10.1210/mend.14.3.0435
73. Partridge JM, Weatherby SJ, Woolmore JA, Highland DJ, Fryer AA, Mann CL, et al. Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes. Neurology (2004) 62:2323-5. doi:10.1212/WNL.62.12.2323
74. Orton SM, Morris AP, Herrera BM, Ramagopalan SV, Lincoln MR, Chao MJ, et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr (2008) 88:441-7.
75. Mamutse G, Woolmore J, Pye E, Partridge J, Boggild M, Young C, et al. Vitamin D receptor gene polymorphism is associated with reduced disability in multiple sclerosis. Mult Scler (2008) 14:1280-3. doi:10.1177/1352458508094643
76. Smolders J, Damoiseaux J, Menheere P, Tervaert JW, Hupperts R. Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol (2009) 207:117-21. doi:10.1016/j.jneuroim.2008.12.011
77. Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K, et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res (1997) 12:915-21. doi:10.1359/jbmr.1997.12.6.915
78. Dickinson J, Perera D, van der Mei A, Ponsonby AL, Polanowski A, Thomson R, et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Mult Scler (2009) 15:563-70. doi:10.1177/1352458509102459
79. Ponsonby AL, Pezic A, Ellis J, Morley R, Cameron F, Carlin J, et al. Variation in associations between allelic variants of the vitamin D receptor gene and onset of type 1 diabetes mellitus by ambient winter ultraviolet radiation levels: a meta-regression analysis. Am J Epidemiol (2008) 168:358-65. doi:10.1093/aje/kwn142
80. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet (2009) 41:703-7. doi:10.1038/ng.381
81. Israni N, Goswami R, Kumar A, Rani R. Interaction of vitamin D receptor with HLA DRB1 0301 in type 1 diabetes patients from North India. PLoS One (2009) 4:e8023. doi:10.1371/journal.pone.0008023
82. Mellanby M, Pattison CL. The action of vitamin D in preventing the spread and promoting the arrest of caries in children. Br Med J (1928) 2:1079-82. doi:10.1136/bmj.2.3545.1079
83. Craelius W. Comparative epidemiology of multiple sclerosis and dental caries. J Epidemiol Community Health (1978) 32:155-65. doi:10.1136/jech.32.3.155
84. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol (2005) 175:4119-26. doi:10.4049/jimmunol.175.6.4119
85. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology (2004) 62:60-5. doi:10.1212/01.WNL.0000101723.79681.38
86. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA (2006) 296:2832-8. doi:10.1001/jama.296.23.2832
87. Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Vitamin D as a protective factor in multiple sclerosis. Neurology (2012) 79:2140-5. doi:10.1212/WNL.0b013e3182752ea8
88. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol (2010) 68:193-203. doi:10.1002/ana.22043
89. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler (2005) 11:266-71. doi:10.1191/1352458505ms1157oa
90. Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol (2010) 67:618-24. doi:10.1002/ana.21972
91. Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol (2011) 10:436-45. doi:10.1016/S1474-4422(11)70045-X
92. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology (2012) 79:261-6. doi:10.1212/WNL.0b013e31825fdec7
93. Loken-Amsrud KI, Holmoy T, Bakke SJ, Beiske AG, Bjerve KS, Bjornara BT, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-beta treatment. Neurology (2012) 79:267-73. doi:10.1212/WNL.0b013e31825fdf01
94. Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol (2014) 71:306-14. doi:10.1001/jamaneurol.2013.5993
95. Becklund BR, Severson KS, Vang SV, DeLuca HF. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci U S A (2010) 107:6418-23. doi:10.1073/pnas.1001119107
96. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology (2010) 74:1852-9. doi:10.1212/WNL.0b013e3181e1cec2
97. Derakhshandi H, Etemadifar M, Feizi A, Abtahi SH, Minagar A, Abtahi MA, et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg (2013) 113:257-63. doi:10.1007/s13760-012-0166-2
98. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology (2011) 77:1611-8. doi:10.1212/WNL.0b013e3182343274
99. Grimaldi L, Barkhof F, Beelke M, Burton J, Holmoy T, Hupperts R, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology (2012) 78:841. doi:10.1212/01.wnl.0000413180.13413.ce
100. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol (2007) 8:285-93. doi:10.1038/ni1433
101. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev (2011) 1(7):CD007470. doi:10.1002/14651858.CD007470.pub2
102. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr (2012) 95:1357-64. doi:10.3945/ajcn.111.031070
103. Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci (2011) 311:44-9. doi:10.1016/j.jns.2011.04.013
104. Hypponen E. Vitamin D and increasing incidence of type 1 diabetes-evidence for an association? Diabetes Obes Metab (2010) 12:737-43. doi:10.1111/j.1463-1326.2010.01211.x
105. Mathieu C. Vitamin D and diabetes: the devil is in the D-tails. Diabetologia (2010) 53:1545-8. doi:10.1007/s00125-010-1791-z
106. Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. The EURODIAB substudy 2 study group. Diabetologia (1999) 42:51-4.
107. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child (2008) 93:512-7. doi:10.1136/adc.2007.128579
108. Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr (1995) 61:638S-45S.
109. Mohr SB, Garland FC, Garland CF, Gorham ED, Ricordi C. Is there a role of vitamin D deficiency in type 1 diabetes of children? Am J Prev Med (2010) 39:189-90. doi:10.1016/j.amepre.2010.03.023
110. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet (2001) 358:1500-3. doi:10.1016/S0140-6736(01)06580-1
111. Takiishi T, Ding L, Baeke F, Spagnuolo I, Sebastiani G, Laureys J, et al. Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term. Diabetes (2014) 63:2026-36. doi:10.2337/db13-1559
112. Gedik O, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia (1986) 29:142-5. doi:10.1007/BF02427083
113. Aljabri KS, Bokhari SA, Khan MJ. Glycemic changes after vitamin D supplementation in patients with type 1 diabetes mellitus and vitamin D deficiency. Ann Saudi Med (2010) 30:454-8. doi:10.4103/0256-4947.72265
114. Nwosu BU, Maranda L. The effects of vitamin D supplementation on hepatic dysfunction, vitamin D status, and glycemic control in children and adolescents with vitamin D deficiency and either type 1 or type 2 diabetes mellitus. PLoS One (2014) 9:e99646. doi:10.1371/journal.pone.0099646
115. Hill AB. The environment and disease: association or causation? Proc R Soc Med (1965) 58:295-300.
116. Wucherpfennig KW, Sethi D. T cell receptor recognition of self and foreign antigens in the induction of autoimmunity. Semin Immunol (2011) 23:84-91. doi:10.1016/j.smim.2011.01.007
117. Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol (2007) 7:904-12. doi:10.1038/nri2190
118. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso-and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest (1985) 53:132-44.
119. Boitard C. T-lymphocyte recognition of beta cells in type 1 diabetes: clinical perspectives. Diabetes Metab (2013) 39:459-66. doi:10.1016/j.diabet.2013.08.001
120. Hafler DA, Weiner HL. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol Rev (1987) 100:307-32. doi:10.1111/j.1600-065X.1987.tb00537.x
121. Wucherpfennig KW, Hafler DA. A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann N Y Acad Sci (1995) 756:241-58. doi:10.1111/j.1749-6632.1995.tb44522.x
122. Severson C, Hafler DA. T-cells in multiple sclerosis. Results Probl Cell Differ (2010) 51:75-98. doi:10.1007/400_2009_9012
123. Gandhi KS, McKay FC, Cox M, Riveros C, Armstrong N, Heard RN, et al. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet (2010) 19:2134-43. doi:10.1093/hmg/ddq090
124. Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, et al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med (2012) 4:153ra131. doi:10.1126/scitranslmed.3004186
125. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science (2014) 344:519-23. doi:10.1126/science.1249547
126. Ye CJ, Feng T, Kwon HK, Raj T, Wilson MT, Asinovski N, et al. Intersection of population variation and autoimmunity genetics in human T cell activation. Science (2014) 345:1254665. doi:10.1126/science.1254665
127. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int (2013) 92:77-98. doi:10.1007/s00223-012-9619-0
128. Holick MF. Vitamin D: a millennium perspective. J Cell Biochem (2003) 88:296-307. doi:10.1002/jcb.10338
129. Whitfield GK, Dang HT, Schluter SF, Bernstein RM, Bunag T, Manzon LA, et al. Cloning of a functional vitamin D receptor from the lamprey (Petromyzon marinus), an ancient vertebrate lacking a calcified skeleton and teeth. Endocrinology (2003) 144:2704-16. doi:10.1210/en.2002-221101
130. Nystad AE, Wergeland S, Aksnes L, Myhr KM, Bo L, Torkildsen O. Effect of high-dose 1.25 dihydroxyvitamin D on remyelination in the cuprizone model. APMIS (2014) 122(12):1178-86. doi:10.1111/apm.12281
131. Wolden-Kirk H, Overbergh L, Christesen HT, Brusgaard K, Mathieu C. Vitamin D and diabetes: its importance for beta cell and immune function. Mol Cell Endocrinol (2011) 347:106-20. doi:10.1016/j.mce.2011.08.016
132. Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem (2010) 285:2227-31. doi:10.1074/jbc.C109.071225
133. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci (2004) 29:664-73. doi:10.1016/j.tibs.2004.10.005
134. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys (2012) 523:9-18. doi:10.1016/j.abb.2011.11.003
135. Hollis BW, Wagner CL. The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab (2013) 98(12):4619-28. doi:10.1210/jc.2013-2653
136. Adams JS, Rafison B, Witzel S, Reyes RE, Shieh A, Chun R, et al. Regulation of the extrarenal CYP27B1-hydroxylase. J Steroid Biochem Mol Biol (2014) 144 Pt A:22-7. doi:10.1016/j.jsbmb.2013.12.009
137. Hine TJ, Roberts NB. Seasonal variation in serum 25-hydroxy vitamin D3 does not affect 1,25-dihydroxy vitamin D. Ann Clin Biochem (1994) 31(Pt 1):31-4. doi:10.1177/000456329403100105
138. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab (1988) 67:373-78. doi:10.1210/jcem-67-2-373
139. Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res (2007) 22(Suppl 2):V28-33. doi:10.1359/jbmr.07s211
140. Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc (2013) 88:720-55. doi:10.1016/j.mayocp.2013.05.011
141. Bener A, Al-Ali M, Hoffmann GF. High prevalence of vitamin D deficiency in young children in a highly sunny humid country: a global health problem. Minerva Pediatr (2009) 61:15-22.
142. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab (2010) 95:471-8. doi:10.1210/jc.2009-1773
143. Grant WB, Peiris AN. Possible role of serum 25-hydroxyvitamin D in black-white health disparities in the United States. J Am Med Dir Assoc (2010) 11:617-28. doi:10.1016/j.jamda.2010.03.013
144. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet (2010) 19:2739-45. doi:10.1093/hmg/ddq155
145. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 376:180-8. doi:10.1016/S0140-6736(10)60588-0
146. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 369:1991-2000. doi:10.1056/NEJMoa1306357
147. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta (2006) 372:33-42. doi:10.1016/j.cca.2006.03.011
148. Batai K, Murphy AB, Shah E, Ruden M, Newsome J, Agate S, et al. Common vitamin D pathway gene variants reveal contrasting effects on serum vitamin D levels in African Americans and European Americans. Hum Genet (2014) 133:1395-405. doi:10.1007/s00439-014-1472-y
149. Murphy AB, Kelley B, Nyame YA, Martin IK, Smith DJ, Castaneda L, et al. Predictors of serum vitamin D levels in African American and European American men in Chicago. Am J Mens Health (2012) 6:420-6. doi:10.1177/1557988312437240
150. Hewison M, Zehnder D, Bland R, Stewart PM. 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol (2000) 25:141-8. doi:10.1677/jme.0.0250141
151. Adams JS, Gacad MA. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med (1985) 161:755-65. doi:10.1084/jem.161.4.755
152. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab (1983) 57:1308-10. doi:10.1210/jcem-57-6-1308
153. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science (1983) 221:1181-3. doi:10.1126/science.6310748
154. Jeffery LE, Wood AM, Qureshi OS, Hou TZ, Gardner D, Briggs Z, et al. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J Immunol (2012) 189:5155-64. doi:10.4049/jimmunol.1200786
155. Stoffels K, Overbergh L, Giulietti A, Verlinden L, Bouillon R, Mathieu C. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res (2006) 21:37-47. doi:10.1359/JBMR.050908
156. Krutzik SR, Hewison M, Liu PT, Robles JA, Stenger S, Adams JS, et al. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol (2008) 181:7115-20. doi:10.4049/jimmunol.181.10.7115
157. Hewison M. Extrarenal CYP27B1 and vitamin D physiology. In: Gombart AF, editor. Vitamin D. Oxidative Stress, Immunity, and Aging. Boca Raton, FL: CRC Press, Taylor & Francis Group (2013). p. 99-127.
158. Fu GK, Lin D, Zhang MY, Bikle DD, Shackleton CH, Miller WL, et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol (1997) 11:1961-70. doi:10.1210/mend.11.13.0035
159. Bikle DD, Nemanic MK, Gee E, Elias P. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest (1986) 78:557-66. doi:10.1172/JCI112609
160. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol (2008) 181:7090-9. doi:10.4049/jimmunol.181.10.7090
161. Liu N, Nguyen L, Chun RF, Lagishetty V, Ren S, Wu S, et al. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology (2008) 149:4799-808. doi:10.1210/en.2008-0060
162. Cross HS, Nittke T, Kallay E. Colonic vitamin D metabolism: implications for the pathogenesis of inflammatory bowel disease and colorectal cancer. Mol Cell Endocrinol (2011) 347(1-2):70-9. doi:10.1016/j.mce.2011.07.022
163. Anderson PH, Hendrix I, Sawyer RK, Zarrinkalam R, Manvis J, Sarvestani GT, et al. Co-expression of C'YP27B1 enzyme with the 1.5 kb CYP27B1 promoter-luciferase transgene in the mouse. Mol Cell Endocrinol (2008) 285:1-9. doi:10.1016/j.mce.2007.12.018
164. O'Brien KO, Li S, Cao C, Kent T, Young BV, Queenan RA, et al. Placental CYP27B1 and CYP24A1 expression in human placental tissue and their association with maternal and neonatal calciotropic hormones. J Clin Endocrinol Metab (2014) 99:1348-56. doi:10.1210/jc.2013-1366
165. Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol (2000) 120:139-46. doi:10.1046/j.1365-2249.2000.01204.x
166. Bell NH, Stern PH, Pantzer E, Sinha TK, DeLuca HF. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest (1979) 64:218-25. doi:10.1172/JCI109442
167. Zerwekh JE, Pak CY, Kaplan RA, McGuire JL, Upchurch K, Breslau N, et al. Pathogenetic role of 1 alpha,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J Clin Endocrinol Metab (1980) 51:381-6. doi:10.1210/jcem-51-2-381
168. Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, et al. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA (2014) 311:2083-91. doi:10.1001/jama.2014.5052
169. Novakovic B, Sibson M, Ng HK, Manuelpillai U, Rakyan V, Down T, et al. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem (2009) 284:14838-48. doi:10.1074/jbc.M809542200
170. Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res (2010) 70:5953-62. doi:10.1158/0008-5472.CAN-10-0617
171. Spanier JA, Nashold FE, Olson JK, Hayes CE. The ifng gene is essential for vdr gene expression and vitamin d3-mediated reduction of the pathogenic T cell burden in the central nervous system in experimental autoimmune encephalomyelitis, a multiple sclerosis model. J Immunol (2012) 189:3188-97. doi:10.4049/jimmunol.1102925
172. Correale J, Ysrraelit MC, Gaitan MI. Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol (2010) 185:4948-58. doi:10.4049/jimmunol.1000588
173. Orton SM, Wald L, Confavreux C, Vukusic S, Krohn JP, Ramagopalan SV, et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology (2011) 76:425-31. doi:10.1212/WNL.0b013e31820a0a9f
174. Carlberg C. Genome-wide (over)view on the actions of vitamin D. Front Physiol (2014) 5:167. doi:10.3389/fphys.2014.00167
175. Carlberg C, Campbell MJ. Vitamin D receptor signaling mechanisms: integrated actions of a well-defined transcription factor. Steroids (2013) 78:127-36. doi:10.1016/j.steroids.2012.10.019
176. Wang Y, Becklund BR, DeLuca HF. Identification of a highly specific and versatile vitamin D receptor antibody. Arch Biochem Biophys (2010) 494:166-77. doi:10.1016/j.abb.2009.11.029
177. Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys (2012) 523:123-33. doi:10.1016/j.abb.2012.04.001
178. Brennan A, Katz DR, Nunn JD, Barker S, Hewison M, Fraher LJ, et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology (1987) 61:457-61.
179. Baeke F, Korf H, Overbergh L, van Etten E, Verstuyf A, Gysemans C, et al. Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D3 in the immune system. J Steroid Biochem Mol Biol (2010) 121:221-7. doi:10.1016/j.jsbmb.2010.03.037
180. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys (2000) 374:334-8. doi:10.1006/abbi.1999.1605
181. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol (2010) 11:344-9. doi:10.1038/ni.1851
182. Nashold FE, Hoag KA, Goverman J, Hayes CE. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol (2001) 119:16-29. doi:10.1016/S0165-5728(01)00360-5
183. Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem (2010) 285:38751-5. doi:10.1074/jbc.C110.185777
184. Mayne CG, Spanier JA, Relland LM, Williams CB, Hayes CE. 1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis. Eur J Immunol (2011) 41:822-32. doi:10.1002/eji.201040632
185. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol (2011) 31:3653-69. doi:10.1128/MCB.05020-11
186. Nashold FE, Spach KM, Spanier JA, Hayes CE. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol (2009) 183:3672-81. doi:10.4049/jimmunol.0901351
187. Chang JH, Cha HR, Lee DS, Seo KY, Kweon MN. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One (2010) 5:e12925. doi:10.1371/journal.pone.0012925
188. Guo C, Gombart AF. The antibiotic effects of vitamin D. Endocr Metab Immune Disord Drug Targets (2014) 14:255-66. doi:10.2174/1871530314666140709085159
189. Tiosano D, Wildbaum G, Gepstein V, Verbitsky O, Weisman Y, Karin N, et al. The role of vitamin D receptor in innate and adaptive immunity: a study in hereditary vitamin D-resistant rickets patients. J Clin Endocrinol Metab (2013) 98:1685-93. doi:10.1210/jc.2012-3858
190. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol (2014) 14:377-91. doi:10.1038/nri3667
191. Wucherpfennig KW, Call MJ, Deng L, Mariuzza R. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr Opin Immunol (2009) 21:590-5. doi:10.1016/j.coi.2009.07.008
192. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol (2002) 3:940-3. doi:10.1038/ni835
193. Disanto G, Watson CT, Meier UC, Ebers GC, Giovannoni G, Ramagopalan SV. Month of birth and thymic output. JAMA Neurol (2013) 70:527-8. doi:10.1001/jamaneurol.2013.2116
194. Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol (2012) 12:669-77. doi:10.1038/nri3279
195. Birnbaum ME, Mendoza JL, Sethi DK, Dong S, Glanville J, Dobbins J, et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell (2014) 157:1073-87. doi:10.1016/j.cell.2014.03.047
196. Marrack P, Scott-Browne J, MacLeod MK. Terminating the immune response. Immunol Rev (2010) 236:5-10. doi:10.1111/j.1600-065X.2010.00928.x
197. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol (2008) 8:523-32. doi:10.1038/nri2343
198. Robinson AP, Harp CT, Noronha A, Miller SD. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handbook Clin Neurol (2014) 122:173-89. doi:10.1016/B978-0-444-52001-2.00008-X
199. Ben-Nun A, Kaushansky N, Kawakami N, Krishnamoorthy G, Berer K, Liblau R, et al. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J Autoimmun (2014) 54:33-50. doi:10.1016/j.jaut.2014.06.004
200. Driver JP, Serreze DV, Chen YG. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol (2011) 33:67-87. doi:10.1007/s00281-010-0204-1
201. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia (1994) 37:552-8. doi:10.1007/BF00403372
202. Branisteanu DD, Waer M, Sobis H, Marcelis S, Vandeputte M, Bouillon R. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J Neuroimmunol (1995) 61:151-60. doi:10.1016/0165-5728(95)00076-E
203. Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A (1996) 93:7861-4. doi:10.1073/pnas.93.15.7861
204. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol (1998) 160:5314-9.
205. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol (2006) 177:6030-7. doi:10.4049/jimmunol.177.9.6030
206. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol (2000) 30:498-508. doi:10.1002/1521-4141(200002)30:2<498::AID-IMMU498>3.3.CO;2-H
207. Nataf S, Garcion E, Darcy F, Chabannes D, Muller JY, Brachet P. 1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J Neuropathol Exp Neurol (1996) 55:904-14. doi:10.1097/00005072-199608000-00006
208. Nashold FE, Miller DJ, Hayes CE. 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol (2000) 103:171-9. doi:10.1016/S0165-5728(99)00247-7
209. Spach KM, Pedersen LB, Nashold FE, Kayo T, Yandell BS, Prolla TA, et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics (2004) 18:141-51. doi:10.1152/physiolgenomics.00003.2004
210. Pedersen LB, Nashold FE, Spach KM, Hayes CE. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res (2007) 85:2480-90. doi:10.1002/jnr.21382
211. Muller K, Gram J, Bollerslev J, Diamant M, Barington T, Hansen MB, et al. Down-regulation of monocyte functions by treatment of healthy adults with 1 alpha,25 dihydroxyvitamin D3. Int J Immunopharmacol (1991) 13:525-30. doi:10.1016/0192-0561(91)90072-F
212. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol (2003) 134:128-32. doi:10.1016/S0165-5728(02)00396-X
213. Drozdenko G, Heine G, Worm M. Oral vitamin D increases the frequencies of CD38+ human B cells and ameliorates IL-17-producing T cells. Exp Dermatol (2014) 23:107-12. doi:10.1111/exd.12300
214. Tang J, Zhou R, Luger D, Zhu W, Silver PB, Grajewski RS, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol (2009) 182:4624-32. doi:10.4049/jimmunol.0801543
215. Bruce D, Yu S, Ooi JH, Cantorna MT. Converging pathways lead to overproduction of IL-17 in the absence of vitamin D signaling. Int Immunol (2011) 23:519-28. doi:10.1093/intimm/dxr045
216. Nashold FE, Nelson CD, Brown LM, Hayes CE. One calcitriol dose transiently increases Helios+FoxP3+ T cells and ameliorates autoimmune demyelinating disease. J Neuroimmunol (2013) 263:64-74. doi:10.1016/j.jneuroim.2013.07.016
217. Kang SW, Kim SH, Lee N, Lee WW, Hwang KA, Shin MS, et al. 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J Immunol (2012) 188:5276-82. doi:10.4049/jimmunol.1101211
218. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, et al. 1,25-dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol (2009) 183:5458-67. doi:10.4049/jimmunol.0803217
219. Kickler K, Ni Choileain S, Williams A, Richards A, Astier AL. Calcitriol modulates the CD46 pathway in T cells. PLoS One (2012) 7:e48486. doi:10.1371/journal.pone.0048486
220. Van Belle TL, Vanherwegen AS, Feyaerts D, De Clercq P, Verstuyf A, Korf H, et al. 1,25-dihydroxyvitamin D3 and its analog TX527 promote a stable regulatory T cell phenotype in T cells from type 1 diabetes patients. PLoS One (2014) 9:e109194. doi:10.1371/journal.pone.0109194
221. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain (2009) 132:1146-60. doi:10.1093/brain/awp033
222. Smolders J, Thewissen M, Peelen E, Menheere P, Cohen Tervaert JW, Damoiseaux J, et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One (2009) 4:e6635. doi:10.1371/journal.pone.0006635
223. Smolders J, Peelen E, Thewissen M, Cohen Tervaert JW, Menheere P, Hupperts R, et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One (2010) 5:e15235. doi:10.1371/journal.pone.0015235
224. Cantorna MT, Humpal-Winter J, DeLuca HF. In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3). Arch Biochem Biophys (2000) 377:135-8. doi:10.1006/abbi.2000.1765
225. Keating P, Munim A, Hartmann JX. Effect of vitamin D on T-helper type 9 polarized human memory cells in chronic persistent asthma. Ann Allergy Asthma Immunol (2014) 112:154-62. doi:10.1016/j.anai.2013.11.015
226. Wang F, Wan L, Zhang C, Zheng X, Li J, Chen ZK. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology (2009) 214:342-9. doi:10.1016/j.imbio.2008.10.007
227. Flugel A, Schwaiger FW, Neumann H, Medana I, Willem M, Wekerle H, et al. Neuronal FasL induces cell death of encephalitogenic T lymphocytes. Brain Pathol (2000) 10:353-64. doi:10.1111/j.1750-3639.2000.tb00267.x
228. Kohji T, Matsumoto Y. Coexpression of Fas/FasL and Bax on brain and infiltrating T cells in the central nervous system is closely associated with apoptotic cell death during autoimmune encephalomyelitis. J Neuroimmunol (2000) 106:165-71. doi:10.1016/S0165-5728(00)00238-1
229. Colucci F, Bergman ML, Penha-Goncalves C, Cilio CM, Holmberg D. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci U S A (1997) 94:8670-4. doi:10.1073/pnas.94.16.8670
230. Comi C, Fleetwood T, Dianzani U. The role of T cell apoptosis in nervous system autoimmunity. Autoimmun Rev (2012) 12:150-6. doi:10.1016/j.autrev.2011.08.011
231. Bieganowska KD, Ausubel LJ, Modabber Y, Slovik E, Messersmith W, Hafler DA. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med (1997) 185:1585-94. doi:10.1084/jem.185.9.1585
232. Saresella M, Marventano I, Speciale L, Ruzzante S, Trabattoni D, Della Bella S, et al. Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. J Neuroimmunol (2005) 166:173-9. doi:10.1016/j.jneuroim.2005.05.010
233. Kohji T, Tanuma N, Aikawa Y, Kawazoe Y, Suzuki Y, Kohyama K, et al. Interaction between apoptotic cells and reactive brain cells in the central nervous system of rats with autoimmune encephalomyelitis. J Neuroimmunol (1998) 82:168-74. doi:10.1016/S0165-5728(97)00198-7
234. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia (1999) 27:62-74. doi:10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S
235. Bechmann I, Steiner B, Gimsa U, Mor G, Wolf S, Beyer M, et al. Astrocyte-induced T cell elimination is CD95 ligand dependent. J Neuroimmunol (2002) 132:60-5. doi:10.1016/S0165-5728(02)00311-9
236. Decallonne B, Mathieu C. Defective activation-induced cell death in NOD T lymphocytes: 1,25-dihydroxyvitamin D3 restores defect. Ann N Y Acad Sci (2003) 1005:176-7. doi:10.1196/annals.1288.021
237. Decallonne B, van Etten E, Giulietti A, Casteels K, Overbergh L, Bouillon R, et al. Defect in activation-induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun (2003) 20:219-26. doi:10.1016/S0896-8411(03)00025-8
238. Decallonne B, van Etten E, Overbergh L, Valckx D, Bouillon R, Mathieu C. 1Alpha,25-dihydroxyvitamin D3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells. J Autoimmun (2005) 24:281-9. doi:10.1016/j.jaut.2005.03.007
239. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 6:1245-52. doi:10.1038/ni1271
240. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, et al. Differential glycosylation of T(H)1, T(H)2 and T(H)-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol (2007) 8(8):825-34. doi:10.1038/ni1482
241. Mkhikian H, Grigorian A, Li CF, Chen HL, Newton B, Zhou RW, et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun (2011) 2:334. doi:10.1038/ncomms1333
242. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol (2010) 11:7-13. doi:10.1038/ni.1818
243. Swierkosz JE, Swanborg RH. Suppressor cell control of unresponsiveness to experimental allergic encephalomyelitis. J Immunol (1975) 115:631-3.
244. Karpus WJ, Swanborg RH. CD4+ suppressor cells differentially affect the production of IFN-gamma by effector cells of experimental autoimmune encephalomyelitis. J Immunol (1989) 143:3492-7.
245. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 155:1151-64.
246. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet (2001) 27:68-73. doi:10.1038/83784
247. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res (2007) 38:112-21. doi:10.1007/s12026-007-0022-2
248. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity (2013) 38:414-23. doi:10.1016/j.immuni.2013.03.002
249. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 14:307-8. doi:10.1038/ni.2554
250. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr Top Microbiol Immunol (2014) 380:39-68. doi:10.1007/978-3-662-43492-5_3
251. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol (2004) 172:5986-93. doi:10.4049/jimmunol.172.10.5986
252. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 19:739-46. doi:10.1038/nm.3179
253. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 421:388-92. doi:10.1038/nature01315
254. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+) FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol (2010) 10:849-59. doi:10.1038/nri2889
255. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 199:971-9. doi:10.1084/jem.20031579
256. Haas J, Hug A, Viehover A, Fritzsching B, Falk CS, Filser A, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol (2005) 35:3343-52. doi:10.1002/eji.200526065
257. Haas J, Fritzsching B, Trubswetter P, Korporal M, Milkova L, Fritz B, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol (2007) 179:1322-30. doi:10.4049/jimmunol.179.2.1322
258. Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, Stinissen P. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol (2008) 180:6411-20. doi:10.4049/jimmunol.180.9.6411
259. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res (2005) 81:45-52. doi:10.1002/jnr.20522
260. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, Rummens JL, et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology (2008) 123:79-89. doi:10.1111/j.1365-2567.2007.02690.x
261. Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol (2008) 28:697-706. doi:10.1007/s10875-008-9236-x
262. Venken K, Hellings N, Liblau R, Stinissen P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med (2010) 16:58-68. doi:10.1016/j.molmed.2009.12.003
263. Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol (2008) 28:677-84. doi:10.1007/s10875-008-9242-z
264. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest (2004) 113:451-63. doi:10.1172/JCI19585
265. Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest (2006) 116:3252-7. doi:10.1172/JCI29251
266. Astier AL. T-cell regulation by CD46 and its relevance in multiple sclerosis. Immunology (2008) 124:149-54. doi:10.1111/j.1365-2567.2008.02821.x
267. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 38:576-86. doi:10.1002/eji.200737271
268. Ma A, Xiong Z, Hu Y, Qi S, Song L, Dun H, et al. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4(+)CD25(+) regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys. Int Immunopharmacol (2009) 9:599-608. doi:10.1016/j.intimp.2009.01.034
269. Ni Choileain S, Astier AL. CD46 processing: a means of expression. Immunobiology (2012) 217:169-75. doi:10.1016/j.imbio.2011.06.003
270. Grzybowski A, Pietrzak K. From patient to discoverer-Niels Ryberg Finsen (1860-1904)-the founder of phototherapy in dermatology. Clin Dermatol (2012) 30:451-5. doi:10.1016/j.clindermatol.2011.11.019
271. Loser K, Beissert S. Regulatory T cells: banned cells for decades. J Invest Dermatol (2012) 132:864-71. doi:10.1038/jid.2011.375
272. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 12:1372-9. doi:10.1038/nm1518
273. Loser K, Beissert S. Regulation of cutaneous immunity by the environment: an important role for UV irradiation and vitamin D. Int Immunopharmacol (2009) 9:587-9. doi:10.1016/j.intimp.2009.01.024
274. Lehmann B, Sauter W, Knuschke P, Dressler S, Meurer M. Demonstration of UVB-induced synthesis of 1 alpha,25-dihydroxyvitamin D3 (calcitriol) in human skin by microdialysis. Arch Dermatol Res (2003) 295:24-8. doi:10.1007/s00403-003-0387-6
275. Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab (2001) 86:4933-8. doi:10.1210/jcem.86.10.7905
276. Kitazawa R, Kitazawa S. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun (2002) 290:650-5. doi:10.1006/bbrc.2001.6251
277. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem (2003) 89:771-7. doi:10.1002/jcb.10567
278. Kim S, Yamazaki M, Zella LA, Meyer MB, Fretz JA, Shevde NK, et al. Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol (2007) 103:430-4. doi:10.1016/j.jsbmb.2006.12.020
279. Bishop KA, Coy HM, Nerenz RD, Meyer MB, Pike JW. Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biol Chem (2011) 286:20880-91. doi:10.1074/jbc.M111.231548
280. Bishop KA, Wang X, Coy HM, Meyer MB, Gumperz JE, Pike JW. Transcriptional regulation of the human TNFSF11 gene in t cells via a cell type-selective set of distal enhancers. J Cell Biochem (2014) 116(2):320-30. doi:10.1002/jcb.24974
281. Gorman S, Kuritzky LA, Judge MA, Dixon KM, McGlade JP, Mason RS, et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol (2007) 179:6273-83. doi:10.4049/jimmunol.179.9.6273
282. Ghoreishi M, Bach P, Obst J, Komba M, Fleet JC, Dutz JP. Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol (2009) 182:6071-8. doi:10.4049/jimmunol.0804064
283. Tomura M, Honda T, Tanizaki H, Otsuka A, Egawa G, Tokura Y, et al. Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest (2010) 120:883-93. doi:10.1172/JCI40926
284. Milliken SV, Wassall H, Lewis BJ, Logie J, Barker RN, Macdonald H, et al. Effects of ultraviolet light on human serum 25-hydroxyvitamin D and systemic immune function. J Allergy Clin Immunol (2012) 129:1554-61. doi:10.1016/j.jaci.2012.03.001
285. Yamazaki S, Nishioka A, Kasuya S, Ohkura N, Hemmi H, Kaisho T, et al. Homeostasis of thymus-derived Foxp3+ regulatory T cells is controlled by ultraviolet B exposure in the skin. J Immunol (2014) 193(11):5488-97. doi:10.4049/jimmunol.1400985
286. Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, et al. Interleukin-10 in the brain. Crit Rev Immunol (2001) 21:427-49. doi:10.1615/CritRevImmunol.v21.i5.20
287. Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med (2008) 8:437-45. doi:10.2174/156652408785160907
288. Engelhardt KR, Grimbacher B. IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms. Curr Top Microbiol Immunol (2014) 380:1-18. doi:10.1007/978-3-662-43492-5_1
289. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 28:546-58. doi:10.1016/j.immuni.2008.02.017
290. Gabrysova L, Howes A, Saraiva M, O'Garra A. The regulation of IL-10 expression. Curr Top Microbiol Immunol (2014) 380:157-90. doi:10.1007/978-3-662-43492-5_8
291. Walter MR. The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr Top Microbiol Immunol (2014) 380:191-212. doi:10.1007/978-3-662-43492-5_9
292. Stohlman SA, Pei L, Cua DJ, Li Z, Hinton DR. Activation of regulatory cells suppresses experimental allergic encephalomyelitis via secretion of IL-10. J Immunol (1999) 163:6338-44.
293. Burkhart C, Liu GY, Anderton SM, Metzler B, Wraith DC. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol (1999) 11:1625-34. doi:10.1093/intimm/11.10.1625
294. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med (2002) 195:603-16. doi:10.1084/jem.20011629
295. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes (2002) 51:1367-74. doi:10.2337/diabetes.51.5.1367
296. Gysemans C, van Etten E, Overbergh L, Giulietti A, Eelen G, Waer M, et al. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes (2008) 57:269-75. doi:10.2337/db07-1095
297. Palmer MT, Lee YK, Maynard CL, Oliver JR, Bikle DD, Jetten AM, et al. Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem (2011) 286:997-1004. doi:10.1074/jbc.M110.163790
298. Zittermann A, Dembinski J, Stehle P. Low vitamin D status is associated with low cord blood levels of the immunosuppressive cytokine interleukin-10. Pediatr Allergy Immunol (2004) 15:242-6. doi:10.1111/j.1399-3038.2004.00140.x
299. Mann EH, Chambers ES, Pfeffer PE, Hawrylowicz CM. Immunoregulatory mechanisms of vitamin D relevant to respiratory health and asthma. Ann N Y Acad Sci (2014) 1317:57-69. doi:10.1111/nyas.12410
300. Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, Cousins DJ, et al. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest (2009) 119:387-98. doi:10.1172/JCI32354
301. Dimeloe S, Richards DF, Urry ZL, Gupta A, Stratigou V, Farooque S, et al. 1alpha,25-dihydroxyvitamin D3 promotes CD200 expression by human peripheral and airway-resident T cells. Thorax (2012) 67:574-81. doi:10.1136/thoraxjnl-2011-200651
302. Urry Z, Chambers ES, Xystrakis E, Dimeloe S, Richards DF, Gabrysova L, et al. The role of 1alpha,25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Eur J Immunol (2012) 42:2697-708. doi:10.1002/eji.201242370
303. Gupta A, Dimeloe S, Richards DF, Chambers ES, Black C, Urry Z, et al. Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma. Thorax (2014) 69:508-15. doi:10.1136/thoraxjnl-2013-203421
304. Chambers ES, Suwannasaen D, Mann EH, Urry Z, Richards DF, Lertmemongkolchai G, et al. 1alpha,25-dihydroxyvitamin D3 in combination with transforming growth factor-beta increases the frequency of Foxp3(+) regulatory T cells through preferential expansion and usage of interleukin-2. Immunology (2014) 143:52-60. doi:10.1111/imm.12289
305. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol (2010) 184:3433-41. doi:10.4049/jimmunol.0904028
306. Getnet D, Grosso JF, Goldberg MV, Harris TJ, Yen HR, Bruno TC, et al. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 47:1595-600. doi:10.1016/j.molimm.2010.02.001
307. Zabransky DJ, Nirschl CJ, Durham NM, Park BV, Ceccato CM, Bruno TC, et al. Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One (2012) 7:e34547. doi:10.1371/journal.pone.0034547
308. Royal W III, Mia Y, Li H, Naunton K. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J Neuroimmunol (2009) 213:135-41. doi:10.1016/j.jneuroim.2009.05.012
309. Smolders J, Menheere P, Thewissen M, Peelen E, Cohen Tervaert JW, Hupperts R, et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol (2010) 121:243-6. doi:10.1016/j.jsbmb.2010.03.001
310. Khoo AL, Koenen HJ, Chai LY, Sweep FC, Netea MG, van der Ven AJ, et al. Seasonal variation in vitamin D(3) levels is paralleled by changes in the peripheral blood human T cell compartment. PLoS One (2012) 7:e29250. doi:10.1371/journal.pone.0029250
311. Guven A, Ecevit A, Sozer O, Tarcan A, Tarcan A, Ozbek N. Correlation between the cord vitamin D levels and regulatory T cells in newborn infants. Eur J Pediatr (2012) 171:1161-6. doi:10.1007/s00431-012-1688-6
312. Baeke F, Korf H, Overbergh L, Verstuyf A, Thorrez L, Van Lommel L, et al. The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J Immunol (2011) 186:132-42. doi:10.4049/jimmunol.1000695
313. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med (2014) 20(12):1410-6. doi:10.1038/nm.3746
314. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 345:1623-7. doi:10.1126/science.1255904
315. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 332:600-3. doi:10.1126/science.1202947
316. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol (2008) 9:194-202. doi:10.1038/ni1549
317. Ni Choileain S, Weyand NJ, Neumann C, Thomas J, So M, Astier AL. The dynamic processing of CD46 intracellular domains provides a molecular rheostat for T cell activation. PLoS One (2011) 6:e16287. doi:10.1371/journal.pone.0016287
318. Cardone J, Le Friec G, Vantourout P, Roberts A, Fuchs A, Jackson I, et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 11:862-71. doi:10.1038/ni.1917
319. Xu YQ, Gao YD, Yang J, Guo W. A defect of CD4+CD25+ regulatory T cells in inducing interleukin-10 production from CD4+ T cells under CD46 costimulation in asthma patients. J Asthma (2010) 47:367-73. doi:10.3109/02770903.2010.481340
320. Ghaffarizadeh A, Flann NS, Podgorski GJ. Multistable switches and their role in cellular differentiation networks. BMC Bioinformatics (2014) 15(Suppl 7):S7. doi:10.1186/1471-2105-15-S7-S7
321. Ross EM, Bourges D, Hogan TV, Gleeson PA, van Driel IR. Helios defines T cells being driven to tolerance in the periphery and thymus. Eur J Immunol (2014) 44:2048-58. doi:10.1002/eji.201343999
322. Baine I, Basu S, Ames R, Sellers RS, Macian F. Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. J Immunol (2013) 190:1008-16. doi:10.4049/jimmunol.1200792
323. Maeki T, Mori Y. Features of human herpesvirus-6A and-6B entry. Adv Virol (2012) 2012:384069. doi:10.1155/2012/384069
324. de Jong BA, Schrijver HM, Huizinga TW, Bollen EL, Polman CH, Uitdehaag BM, et al. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann Neurol (2000) 48:641-6. doi:10.1002/1531-8249(200010)48:4<641::AID-ANA11>3.0.CO;2-Z
325. Martinez Doncel A, Rubio A, Arroyo R, de las Heras V, Martin C, Fernandez-Arquero M, et al. Interleukin-10 polymorphisms in Spanish multiple sclerosis patients. J Neuroimmunol (2002) 131:168-72. doi:10.1016/S0165-5728(02)00248-5
326. Almeras L, Meresse B, Seze J, De Lefranc D, Dubucquoi S, Fajardy I, et al. Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. Eur Cytokine Netw (2002) 13:200-6.
327. Luomala M, Lehtimaki T, Huhtala H, Ukkonen M, Koivula T, Hurme M, et al. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand (2003) 108:396-400. doi:10.1034/j.1600-0404.2003.00165.x
328. Myhr KM, Vagnes KS, Maroy TH, Aarseth JH, Nyland HI, Vedeler CA. Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J Neurol Sci (2002) 202:93-7. doi:10.1016/S0022-510X(02)00246-0
329. Dyment DA, Cader MZ, Chao MJ, Lincoln MR, Morrison KM, Disanto G, et al. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology (2012) 79:406-11. doi:10.1212/WNL.0b013e3182616fc4
330. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 19:683-765. doi:10.1146/annurev.immunol.19.1.683